Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: J Hepatol. 2008 May 22;49(2):251–261. doi: 10.1016/j.jhep.2008.04.015

Figure 7. CPT-2-Me-cAMP mediated protection from GCDC induced FAK dephosphorylation is partially PI3K dependent.

Figure 7

Hepatocytes plated on Type 1 collagen were treated with 50 nM wortmannin, 20 uM CPT-2-Me-cAMP or sequentially with 50 nM wortmannin and 20 uM CPT-2-Me-cAMP and then for 2 hrs with GCDC. The amount of FAKTyr397 was determined by immunoblotting. The results of 4 separate experiments were quantified and the mean and the standard deviation presented graphically. The * indicated the value is statistically different than that seen in control (untreated) hepatocytes, the # indicates the value is significantly different from that seen with GCDC treatment alone and the + indicates the value is significantly different from that seen with combined CPT-2-Me-cAMP and GCDC treatment.